Avanir Pharmaceuticals (AVNR) Reports In-Line Q2 EPS

Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $10.29 million.

For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Tencent Holdings (700:HK) (TCEHY) PT Lowered to HK$625 at Benchmark to Reflect Downward Earnings Revisions
• Axos Financial (AX) PT Raised to $120 at Benchmark